Sermorelin has elevated IGF-1, shifted body composition, and preserved pituitary feedback across controlled trials — here is what the studies measured.

What Is Sermorelin?

Sermorelin (GHRH 1-29 NH2) is a 29-amino-acid synthetic peptide — the truncated active fragment of endogenous growth hormone-releasing hormone (GHRH), which spans 44 residues. Despite retaining only 29 of the original amino acids, it binds the GHRH receptor on pituitary somatotrophs with full biological activity ^[6]. The compound was developed as a shorter, more manufacturable analog of the natural hypothalamic signal that instructs the pituitary to release growth hormone.

Sermorelin acetate (brand name Geref) held FDA approval for pediatric growth hormone deficiency from the 1990s through 2008, when the manufacturer voluntarily withdrew the product due to discontinuation of the active pharmaceutical ingredient — not due to safety concerns ^[1]. That regulatory history distinguishes it from most research peptides: sermorelin has a documented human clinical record spanning multicenter pediatric trials, NIH-supported adult aging studies, and a JAMA-published randomized controlled trial in HIV-associated lipodystrophy ^[2][4][10].

The mechanism is specific. Sermorelin binds the GHRH receptor (GHRHR), a Class B G protein-coupled receptor located on anterior pituitary somatotrophs, and triggers a cAMP-PKA-CREB signaling cascade that upregulates GH mRNA transcription and stimulates pulsatile GH secretion ^[6]. Because this works through the pituitary's own synthesis-and-release machinery — rather than bypassing it with exogenous GH — negative feedback via somatostatin and IGF-1 remains intact. The GH response is physiological, pulsatile, and self-limiting ^[5].

What does Sermorelin do to the body?

Sermorelin binds GHRH receptors in the anterior pituitary, stimulating synthesis and pulsatile release of endogenous growth hormone; downstream effects include IGF-1 elevation and associated anabolic signaling ^[6]. The key distinction from exogenous GH is preservation of pituitary feedback — somatostatin continues to govern GH release, preventing supraphysiological GH/IGF-1 states ^[5].

In the Vitiello 2001 aging study, once-nightly subcutaneous administration at approximately 14 mcg/kg elevated IGF-1 by approximately 35%, reduced body fat (primarily visceral abdominal fat), and increased lean body mass by approximately 5% on DEXA over 5-6 months ^[4]. A JAMA 2004 randomized controlled trial using 1 mg subcutaneously twice daily in HIV-infected men with lipodystrophy raised mean IGF-1 by 104 ng/mL versus 6 ng/mL placebo (P=0.004), increased lean mass 0.9 kg, and reduced visceral adipose tissue 19.2 cm² versus an increase of 2.3 cm² in controls ^[10].

These findings document what the molecule does in controlled research populations. Downstream interpretation of those changes — what they mean for individual physiology or health — is outside the scope of this site's editorial mandate.

Sermorelin Peptide Therapy: Research Overview

In research contexts, sermorelin peptide therapy refers to protocols using subcutaneous sermorelin administration to stimulate pituitary GH release — as distinct from exogenous recombinant human GH injection, which bypasses pituitary signaling entirely. The distinction matters mechanistically: sermorelin preserves pituitary feedback regulation, maintains pulsatile GH release patterns, and avoids the tachyphylaxis risk associated with continuous exogenous GH exposure ^[5].

A 2006 Walker review in Clinical Interventions in Aging outlined the theoretical and physiological advantages: preserved somatostatin and IGF-1 negative feedback preventing overdosing, pulsatile release avoiding receptor desensitization, and stimulation of pituitary GH gene transcription maintaining neuroendocrine axis integrity ^[5]. The pediatric GHD literature from the Geref era provides the most robust human evidence: the Geref International Study Group multicenter trial reported that 74% of 110 GH-deficient children responded favorably in the first year, with mean height velocity increasing from 4.1 ± 0.9 cm/yr at baseline to 8.0 ± 1.5 cm/yr at 6 months ^[2].

Post-approval adult data is less voluminous but exists. The NIH-supported University of Washington work (Vitiello, Merriam et al.) documented body composition and cognitive outcomes over 5-6 months ^[4]. The Sigalos 2017 combination secretagogue study in hypogonadal men provided supplementary data on IGF-1 response using sermorelin alongside ghrelin-receptor agonists ^[9]. See the sermorelin dosage and sermorelin side effects pages for administration and safety details from the research record.

Is Sermorelin a steroid?

No. Sermorelin is a peptide hormone analog — a short chain of amino acids — not a steroid. Steroids are lipid-derived molecules with a characteristic four-ring carbon skeleton; they operate on nuclear steroid hormone receptors. Sermorelin is a 29-amino-acid polypeptide with a molecular weight of approximately 3,357.9 Da that operates on a cell-surface G protein-coupled receptor (GHRHR) on pituitary somatotrophs ^[6]. The two structural classes are completely distinct.

Sermorelin is also not a controlled substance in the United States. It requires a prescription (Schedule V equivalent in most US pharmacy contexts) but is not listed in the DEA Controlled Substances schedules. Athletes subject to WADA code face a separate prohibition: Sermorelin is classified as S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics) on the WADA Prohibited List due to its GH-stimulating activity ^[1].

Sermorelin peptide classification

Yes. Sermorelin is a 29-amino-acid synthetic peptide — specifically a truncated analog of the 44-residue endogenous GHRH, retaining full biological activity at the GHRH receptor ^[6]. Molecular weight: approximately 3,357.9 Da. It belongs to the class of GHRH analogs alongside longer or modified analogs studied in the same body-composition and endocrine-axis literature. Its short-chain structure accounts for its rapid plasma clearance: plasma half-life via intravenous administration is approximately 4.3 ± 1.4 minutes (Soule 1994) ^[7].

For a detailed breakdown of sermorelin dosage protocols studied in the literature, see the dedicated dosage page. For the mechanistic record and comparative analyses, see the growth hormone-releasing hormone research page.

Research applications of Sermorelin

Research applications across the published literature include: growth hormone deficiency evaluation (diagnostic stimulus testing), pediatric growth failure (the historical FDA indication under NDA 020443 for Geref, 1991–2008) ^[1][2][3], adult GH decline and body composition in aging cohorts ^[4][5], HIV-associated lipodystrophy (JAMA 2004 RCT) ^[10], GH pulsatility and neuroendocrine axis characterization ^[6][8], and as a component of combination GH secretagogue protocols in hypogonadal men ^[9].

A 2025 Nature Reviews Endocrinology review (Granata, Schally et al.) documented GHRH analog applications extending beyond pituitary GH stimulation: wound healing, inflammation, immune function, neuroprotection, cardiovascular disease, metabolic disorders, and neurodegenerative conditions — mediated through peripheral GHRH receptors ^[17]. Class-level mechanistic evidence for these applications was additionally reviewed in a 2025 Reviews in Endocrine & Metabolic Disorders analysis of GHRHR signaling (Halmos, Schally) ^[6].

See frequently asked questions for answers to the most common questions from the published record, or jump directly to the sermorelin side effects literature.